Editorial: The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease (TRC-PAD) - A Fundamental Ally in AD Prevention Research
- PMID: 32920620
- DOI: 10.14283/jpad.2020.41
Editorial: The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease (TRC-PAD) - A Fundamental Ally in AD Prevention Research
Conflict of interest statement
Dr. Porsteinsson reports personal fees from Acadia Pharmaceuticals, Avanir, Cadent Therapeutics, Eisai, Functional Neuromodulation, and Tetra Discovery Partners; grants to his institution from Avanir, Biogen, Biohaven, Eisai, Eli Lilly, Genentech/Roche, Novartis, outside of the submitted work. Dr. Clark has nothing to disclose.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical